(Q39122846)

9 September 2017

title

Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies (English)

1 reference

9 September 2017

1 reference

Brian D Harms

1

1 reference

9 September 2017

Jeffrey D Kearns

series ordinal

2

1 reference

9 September 2017

Sergio Iadevaia

series ordinal

3

1 reference

9 September 2017

Alexey A Lugovskoy

series ordinal

4

1 reference

9 September 2017

publication date

18 July 2013

1 reference

9 September 2017

1 reference

9 September 2017

volume

65

1 reference

9 September 2017

issue

1

1 reference

9 September 2017

page(s)

95-104

1 reference

Continuous cultures of fused cells secreting antibody of predefined specificity

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Monoclonal antibody therapy of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

The future of antibodies as cancer drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Current aspects of the structure, function, and genetics of the immunoglobulins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Structural basis of antibody function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Contrasting IgG Structures Reveal Extreme Asymmetry and Flexibility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Fc receptors and their interactions with immunoglobulins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Conformations of immunoglobulin hypervariable regions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Use of staphylococcal protein A as an immunological reagent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Antibody engineering by parsimonious mutagenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

High resolution functional analysis of antibody-antigen interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Phage antibodies: filamentous phage displaying antibody variable domains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Assembly of combinatorial antibody libraries on phage surfaces: the gene III site

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

By-passing immunization. Human antibodies from V-gene libraries displayed on phage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Isolation of anti-T cell receptor scFv mutants by yeast surface display

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Yeast surface display for screening combinatorial polypeptide libraries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

In vitro selection and evolution of functional proteins by using ribosome display

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

CIS display: In vitro selection of peptides from libraries of protein-DNA complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Production and fluorescence-activated cell sorting of Escherichia coli expressing a functional antibody fragment on the external surface

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Isolation of high affinity human antibodies directly from large synthetic repertoires.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Improving antibody affinity by mimicking somatic hypermutation in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Rapid optimization and prototyping for therapeutic antibody-like molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Stability engineering of scFvs for the development of bispecific and multivalent antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Stability engineering of antibody single-chain Fv fragments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

IgG2m4, an engineered antibody isotype with reduced Fc function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Engineered antibody Fc variants with enhanced effector function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Structural characterization of a mutated, ADCC-enhanced human Fc fragment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Modulation of the effector functions of a human IgG1 through engineering of its hinge region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Enhanced antibody half-life improves in vivo activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Engineered human IgG antibodies with longer serum half-lives in primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Soluble monomeric IgG1 Fc.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

A large library based on a novel (CH2) scaffold: identification of HIV-1 inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Affinity and avidity in antibody-based tumor targeting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Bispecific antibodies for cancer therapy: the light at the end of the tunnel?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Mechanism of binding of multivalent immune complexes to Fc receptors. 2. Kinetics of binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

The influence of polyvalency on the binding properties of antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

The effect of co-operativity on the equilibrium binding of symmetric bivalent ligands to antibodies: theoretical results with application to histamine release from basophils

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Kinetic analysis of histamine release due to covalently linked IgE dimers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Investigation of early events in Fc epsilon RI-mediated signaling using a detailed mathematical model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Optimizing properties of antireceptor antibodies using kinetic computational models and experiments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Dynamics of antibodies from cryo-electron tomography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Bivalent binding of a neutralising antibody to a calicivirus involves the torsional flexibility of the antibody hinge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Automated kinetic exclusion assays to quantify protein binding interactions in homogeneous solution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

BiTEs: bispecific antibody constructs with unique anti-tumor activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Design and production of novel tetravalent bispecific antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Anti-MET targeted therapy has come of age: the first durable complete response with MetMAb in metastatic gastric cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Rational engineering of antibody therapeutics targeting multiple oncogene pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

High affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2013.07.017

10.1016/J.YMETH.2013.07.017

7 January 2021

Identifiers

DOI

1 reference

release_twp6cfbehfef7hou2okns5baxy

9 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/twp6cfbehfef7hou2okns5baxy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference